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ttp://dx.doi.org/10.1016/j.ajpath.2013.08.016Pulmonary arterial hypertension (PAH) is characterized by elevated pulmonary arterial pressure with
lumen-occluding neointimal and plexiform lesions. Activation of store-operated calcium entry channels
promotes contraction and proliferation of lung vascular cells. TRPC4 is a ubiquitously expressed store-
operated calcium entry channel, but its role in PAH is unknown. We tested the hypothesis that TRPC4
promotes pulmonary arterial constriction and occlusive remodeling, leading to right ventricular failure in
severe PAH. Severe PAH was induced in SpragueeDawley rats and in wild-type and TRPC4-knockout Fischer
344 rats by a single subcutaneous injection of SU5416 [SU (semaxanib)], followed by hypoxia exposure
(Hx; 10% O2) for 3 weeks and then a return to normoxia (Nx; 21% O2) for 3 to 10 additional weeks (SU/Hx/
Nx). Although rats of both backgrounds exhibited indistinguishable pulmonary hypertensive responses to
SU/Hx/Nx, Fischer 344 rats died within 6 to 8 weeks. Normoxic and hypertensive TRPC4-knockout rats
recorded hemodynamic parameters similar to those of their wild-type littermates. However, TRPC4 inac-
tivation conferred a striking survival beneﬁt, due in part to preservation of cardiac output. Histological
grading of vascular lesions revealed a reduction in the density of severely occluded small pulmonary ar-
teries and in the number of plexiform lesions in TRPC4-knockout rats. TRPC4 inactivation therefore provides
a survival beneﬁt in severe PAH, associated with a decrease in the magnitude of occlusive remodeling.
(Am J Pathol 2013, 183: 1779e1788; http://dx.doi.org/10.1016/j.ajpath.2013.08.016)Supported by NIH grants P01-HL066299 and R37-HL060024 (T.S.),
R21-HL106101 (M.O.), and R01-OD010944 (M.A.).Pulmonary arterial hypertension is characterized by
increased pulmonary vascular resistance and arterial pres-
sure, processes that culminate in right ventricular failure and
death.1 Intractable pulmonary vasoconstriction and occlu-
sive vascular remodeling are integral to the pathogenesis of
this syndrome.2 These processes are causally linked to
perturbations in the normal balance of vasoactive, mito-
genic, and apoptotic factors in pulmonary vascular cells.3
Currently available therapeutic options (such as calcium
channel blockers, prostacyclin analogs, endothelin-1 recep-
tor antagonists, phosphodiesterase inhibitors, and nitric
oxide) seek principally to reduce vasoconstriction.4 These
therapeutic options only minimally decrease pulmonary
arterial pressure and, with the possible exception of calcium
channel blockers in a certain population of patients,5 they do
not affect disease progression. Despite recent improvements
in patient outcomes, the persistently high morbidity andstigative Pathology.
.mortality for pulmonary arterial hypertension has prompted
a search for signaling nodes within vascular cells that are
mechanistically linked to disease progression and that, as
such, represent novel therapeutic options with the potential
for improved patient functional status and survival.6
Cytosolic calcium is a second messenger that represents
one such signaling node, or convergence site.7 In pulmonary
arterial hypertension, multiple inﬂammatory cytokines,
growth factors, and vasoactive autocoids act on trans-
membrane receptors and chronically elevate cytosolic cal-
cium; cytosolic calcium is constitutively elevated in both
endothelial8 and smooth muscle cells9 from pulmonary
arterial hypertension patients. In endothelial cells, increased
cytosolic calcium is a stimulus for proliferation, and has
Alzoubi et albeen incriminated in the formation of occlusive lesions
within small pulmonary arterioles.10 In smooth muscle cells,
increased cytosolic calcium represents a stimulus for both
contraction and proliferation, and has been incriminated in
hypercontraction, hypertrophy, and hyperplasia of the
medial wall.11 However, the source of elevated calcium in
endothelial and smooth muscle cells obtained from pulmo-
nary arterial hypertensive patients is poorly understood.
Sustained elevations in cytosolic calcium require calcium
inﬂux through transmembrane channels. The principal cal-
cium channels in pulmonary arterial endothelial cells are
receptor- and store-operated calcium entry channels,
whereas smooth muscle cells also possess voltage-gated
calcium channels.12 Data from Yuan and colleagues9 and
Lin et al13 suggest that, among these mechanisms of calcium
inﬂux, store-operated calcium entry critically contributes to
vascular cell proliferation.
Transient receptor potential proteins of the canonical
TRPC subfamily comprise store-operated calcium entry
channel subunits.14,15 TRPC1 and TRPC4, in particular,
interact to form a heterotetramer calcium channel,16
although the molecular basis of this channel signalplex
(ie, signaling complex) is incompletely resolved. Activation
of calcium entry through the TRPC1/4 channel requires
TRPC4 binding to protein 4.1 near the pore within the
carboxy-terminus.15 Protein 4.1 in turn binds to the spectrin
membrane skeleton that links the TRPC1/4 channel signal-
plex to the endoplasmic reticulum. Few ion channels are
gated by protein 4.1.17 However, another store-operated
calcium entry channel, Orai1, also possesses a putative
protein 4.1 binding domain and can be resolved within the
TRPC1/4 signalplex, where it constitutively interacts with
TRPC4.18 Orai1 forms the molecular basis for a highly
calcium selective channel responsible for the calcium
release-activated calcium current, ICRAC,
19 and it also con-
tributes to calcium selectivity of the TRPC1/4 channel,20
suggesting that TRPC4 is essential for proper organization
of the store-operated calcium entry signalplex. Given that
TRPC4 is essential to the molecular make-up of store-
operated calcium entry channels, and because it has been
incriminated in the activation of endothelial nitric oxide
synthase,21,22 endothelial cell barrier disruption,23 and
smooth muscle cell contraction, hyperproliferation, and
mitogenesis,11 we sought to determine whether TRPC4
contributes to development of severe pulmonary arterial
hypertension. To this end, we tested the hypothesis that
TRPC4 promotes pulmonary arterial constriction and
occlusive remodeling leading to right ventricular failure in
severe pulmonary arterial hypertension.
Materials and Methods
Animals
All experimental procedures were performed in accordance
with current provisions of the U.S. Animal Welfare Act and1780were approved by the Institutional Animal Care and Use
Committee of the University of South Alabama. Severe
occlusive pulmonary arterial hypertension in rats was
induced by a single subcutaneous injection of 20 mg/kg
SU5416 [SU (semaxanib)] (Cayman Chemical, Ann Arbor,
MI) on day 1, followed by exposure to 3 weeks of nor-
mobaric hypoxia (Hx; 10% O2) and then re-exposure to
normoxia (Nx; 21% O2) for 3 to 10 additional weeks (SU/
Hx/Nx). The hemodynamic and histopathological parame-
ters of pulmonary arterial hypertension were compared
among three experimental groups of age- and weight-
matched rats: male Sprague-Dawley (SD), male Fischer
344 (F344), and male TRPC4-knockout (KO) F344. Each
experimental group included a set of normoxic time-control
rats. TRPC4-KO F344 rats were generated by Transposagen
Biopharmaceuticals (Lexington, KY), as part of the
Knockout Rat Consortium (Trpc4tm1Bni, targeted mutation 1,
Bernd Nilius), and were bred and genotyped both at
Transposagen and at the University of South Alabama.
Genotyping of the TRPC4-KO Rats
Rat tail snips were collected according to the guidelines of
the University of South Alabama Animal Care and Use
Committee. DNA was extracted from tail snips, as described
previously,24 and 2 mL of the resulting DNA solution
was subjected to PCR analysis using three primers (primer
A, 50-GTGTTGGTCTCCATTACTTCAGCT-30; primer B,
50-ATTCTTCCCTTTGAGCCCACT-30; and transposon
primer, 50-CTGACCTAAGACAGGGAATT-30) in a total
volume of 20 mL containing 1 GoTaq Green PCR master
mix (Promega, Madison, WI) and 1 mmol/L of each primer.
The cycling parameters were denaturation at 94C for 5
minutes; then 30 cycles of 94C for 30 seconds, 54C for 30
seconds, and 72C for 1 minute; and extension at 72C for 7
minutes.
Basal Calcium Dynamics
Rat pulmonary artery segments (w500 mm in length) were
dissected, cut open longitudinally, and mounted intima side
up on Sylgard blocks (Dow Corning, Midland, MI) for
endothelial imaging, as described previously.25,26 Arteries
were incubated with Ca2þ indicator loading solution (Life
Technologies, Carlsbad, CA) containing 15 mmol/L Fluo-4
AM and 0.06% Pluronic F-127 in HEPES (pH 7.45) at
room temperature for 40 minutes in the dark. After a wash,
blocks were placed face down on two parallel 100-mm
supporting pins in a glass-bottom chamber containing
HEPES. The chamber was mounted on an inverted micro-
scope ﬁtted with a PerkinElmer (Waltham, MA) spinning
disk RS-3 confocal unit. Ca2þedependent ﬂuorescence (488
nm excitation, 510 nm emission) was measured at 8 frames
per second at 25C (20 objective) using UltraVIEW
software version 1.1.0.9 (PerkinElmer). Only recordings
with >90% of total viewable area in focus were processedajp.amjpathol.org - The American Journal of Pathology
TRPC4 and Mortality in Severe PAHand analyzed. Dynamic basal data were processed using a
custom algorithm25,26 implemented as a plug-in with ImageJ
software version 1.47 (NIH, Bethesda, MD) speciﬁcally
designed to i) detect sites of dynamic Ca2þ change above
statistical noise (P < 0.01), ii) deﬁne regions of interest
(ROI; 5 pixel or 1.7 mm diameter) at active site centers, and
iii) analyze average ﬂuorescence intensities at ROIs to
determine speciﬁc event parameters (amplitude, duration,
and spread). Fluorescence data are expressed as the F/F0
ratio, where F0 is determined by a linear regression of base
data at each ROI. For acetylcholine (ACh) responses,
average Ca2þedependent ﬂuorescence was assessed over a
ﬁeld of 2.8  104 mm (approximately 80 cells).
Echocardiography
Echocardiography was performed using a Vevo 770 imag-
ing system (VisualSonics, Toronto, ON, Canada) at baseline
and at the end of weeks 5 and 8, to evaluate the progression
of cardiac dysfunction. Rats were anesthetized but were kept
spontaneously breathing using isoﬂurane 2.0% in a 1:1 O2/
air mixture. Two-dimensional, M-mode, and Doppler ﬂow
imaging was performed with a 30-MHz probe. Measure-
ments of cardiac output (CO), left ventricular end-diastolic
volume (LVEDV), tricuspid annular plane systolic excursion
(TAPSE), and pulmonary artery acceleration time (PA-AT)
were acquired as previously reported.27
Hemodynamic Measurements in Catheterized Rats
Rats were anesthetized with 30 mg/kg i.p. pentobarbital so-
dium. A polyvinyl catheter (PV-1; internal diameter, 0.28
mm) was inserted into the right ventricle via the right jugular
vein for measurement of right ventricular systolic pressure
(RVSP). A microtip P-V1 catheter (SPR-838; Millar In-
struments, Houston, TX) was inserted into the right carotid
artery and advanced into the left ventricle. Left ventricular
systolic pressure (LVSP) and CO were measured. Cardiac
index (CI) was calculated by dividing CO by body weight.
Isolated Arterial Ring Studies
Extralobar ﬁrst-branch pulmonary artery and 3-mm-long
thoracic aorta rings were placed into isometric tension baths
containing 10 mL of Earle’s balanced salt solution bubbled
with 21% O2e5% CO2e74% N2 gas at 37C. Isolated ar-
teries were brought to a resting tension of 1 g (aorta), 0.75 g
(normotensive pulmonary artery), or 1.5 g (hypertensive
pulmonary artery) and were equilibrated at this tension for
60 minutes, as described previously.28 Next, 80 mmol/L
KCl was injected into the bath, to elicit a maximum con-
tractile response. The bath was washed with Earle’s
balanced salt solution, and 1 mmol/L phenylephrine (PE)
was subsequently added. The time to peak PE contraction
was recorded, and then 10 mmol/L ACh was administered to
evaluate endothelium-dependent relaxation.The American Journal of Pathology - ajp.amjpathol.orgMorphometric Analysis of Pulmonary Vascular and
Cardiac Remodeling
Rat lungs were ﬁxed for histological analysis by tracheal
instillation of a mixture of 1% formalin and 0.5% agarose
under constant pressure (20 cmH2O). After immersion in
10% formalin for 48 hours, lung tissue was cut into sections
5 mm thick, placed in 70% ethanol, embedded in parafﬁn,
serially mounted onto Superfrost Plus slides (Thermo Fisher
Scientiﬁc, Waltham, MA), and stained with H&E. Vascular
occlusion density (OD) was assessed in a masked fashion by
ﬁve independent observers (A.A., P.A., K.O., M.O., and
T.S.) by grading the small (<50 mm) pulmonary arteries in
at least three lung tissue samples per group as OD Z 0 (no
occlusion), OD 50%, or OD >50%. The same vessels
were then classiﬁed according to the HeatheEdwards
pathological grading of pulmonary vascular remodeling.29
Formalin-ﬁxed, parafﬁn-embedded heart tissue was
stained with Masson’s trichrome stain to assess the degree
of ﬁbrosis within the heart tissue. Images were acquired
using a Nikon (Tokyo, Japan) E600 light microscope with a
digital interface Q-imaging software. Fibrosis was estimated
as the percentage of blue-stained tissue areas (collagen ﬁ-
bers stain blue) relative to the total surface area.Statistical Analysis
Data are expressed as means  SEM, unless speciﬁed other-
wise. Unpaired nonparametric t-test or analysis of variance
with Bonferroni post hoc test were used for comparisons
among the experimental groups. Survival results were plotted
on a KaplaneMeier curve and analyzed using a ManteleCox
log-rank test. For histological grading studies, we used a
contingency test, with CochraneManteleHaenszel adjust-
ment, where likelihood ratio and Pearson’s P value were
calculated. Differences were considered statistically signiﬁ-
cant at P < 0.05.Results
Both SD and F344 Rats Develop Severe Pulmonary
Arterial Hypertension
The novel strain of genetically modiﬁed rats used in this
study was bred on an F344 background. Because F344 rats
have not previously been exposed to SU/Hx/Nx, we ﬁrst
sought to conﬁrm that they respond to this treatment with
development of pulmonary arterial hypertension. Baseline
hemodynamic parameters were similar in SD and F344 rats
(data not shown). Eight weeks of SU/Hx/Nx in both SD and
F344 rats produced a similar range of changes in RVSP, CI,
LVSP, and right ventricular hypertrophy index [RV weight/
(LV þ septum weight)] (Figure 1). SD and F344 rats
therefore develop a similar hemodynamic response to in-
duction of severe pulmonary arterial hypertension.1781
Figure 1 Rats of SD and F344 backgrounds develop severe pulmonary
arterial hypertension. Eight weeks of SU/Hx/Nx exposure induced similar
changes in RVSP (A), CI (B), LVSP (C), and the right ventricular hypertrophy
index (D) in both strains of rats. For comparison, normotensive values from
previous studies in SD rats (historic controls) are indicated by dotted lines.
Data are expressed as means  SEM. n Z 4 per group.
Alzoubi et alTRPC4 Inactivation Causes a Calcium Signaling Defect
in Pulmonary Artery Endothelium
F344 rats were genotyped to conﬁrm the successful inacti-
vation of TRPC4 and to generate wild-type (WT) littermateFigure 2 TRPC4-KO rats exhibit a defect in ACh-induced calcium inﬂux. A: Gen
artery segments were isolated and loaded with the Fluo-4 AM cytosolic calcium ind
shape revealed a distinct anatomical pattern among WT and TRPC4-KO vess
Ca2þedependent ﬂuorescence recorded in open artery preparations of WT and TR
cillations. Top panels: Representative tracings of dynamic cytosolic Ca2þ events
(5 mm diameter) from a different cell. Bottom panels: Total sites and events per
signal stimulated by 2 mmol/L ACh in pulmonary artery endothelium of WT and TRP
after 120 seconds. Data are expressed as means  SEM. n Z 4. *P < 0.05 versu
1782controls (Figure 2A). WT rats expressed a fragment of 905
bp, KO rats expressed a fragment of 510 bp, and hetero-
zygotic rats expressed both fragments.
Once animals were genotyped, we sought to determine
whether TRPC4-deﬁcient animals exhibited a calcium
signaling defect characteristic of the absence of a functional
store-operated calcium entry channel.22 WT and KO F344
rats were selected after genotyping, and pulmonary arteries
were harvested for study. Vessel segments were loaded with
calcium dye and pulmonary artery endothelium was imaged
en face. Gross inspection of the ﬂuorescence signal obtained
from dye-loaded endothelium revealed regular polyhedral
endothelial organization, only slightly elongated toward the
direction of ﬂow, in WT animals (Figure 2B). In animals
exhibiting TRPC4 inactivation, however, endothelium was
irregularly spaced and elongated in the direction of ﬂow, an
observation consistent across all of the vessels studied.
These data suggest that TRPC4 inactivation repatterns the
pulmonary endothelium.
Although endothelial cell cytosolic calcium averages
approximately 100 nmol/L over extended time periods,
there are dynamic ﬂuctuations in cytosolic calcium from
moment to moment. We therefore measured basal cytosolic
calcium dynamics for 2 minutes at 8 Hz frequency. ROIs
were identiﬁed within individual cells based on a threshold
excursion criterion of greater than two-fold transient in-
creases in cytosolic calcium,25,26 and cytosolic calcium inotyping of TRPC4 WT, heterozygotic (Het), and KO F344 rats. B: Pulmonary
icator. Endothelium was then imaged en face. Evaluation of endothelial cell
els, with elongated endothelium in TRPC4-KO rats. C: Basal cytosolic
PC4-KO rats revealed no difference in basal cytosolic calcium dynamic os-
occurring in individual cells over 2 minutes. Each line represents the ROI
ﬁeld per minute (n Z 4 per group). D: Average whole-ﬁeld cytosolic Ca2þ
C4-KO rats over time, as well as peak Ca2þ response and steady-state signal
s WT.
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Figure 3 TRPC4-KO rats exhibit a survival beneﬁt that cannot be
explained by improved hemodynamic response to SU/Hx/Nx. A: Survival
over 12 weeks of SU/Hx/Nx exposure. SD rats (dotted line) serve as historic
controls. TRPC4-KO rats (n Z 12) exhibited a clear survival beneﬁt versus
WT rats (nZ 6) after induction of severe pulmonary arterial hypertension.
B: M-mode echocardiography of the left ventricle revealed a smaller LVEDV
in WT rats after SU/Hx/Nx exposure. CeE: Development of pulmonary
arterial hypertension was associated with decrements in CO (C), TAPSE (D),
and PA-AT (E) in WT (nZ 8) and KO (nZ 12) rats. Echocardiography was
performed at baseline and after 8 weeks of SU/Hx/Nx exposure. Data are
expressed as means  SEM. *P < 0.05 versus control. yP < 0.0006 versus
WT, ManteleCox log-rank test.
Figure 4 TRPC4 inactivation did not signiﬁcantly impair either the
maximal smooth muscle cell constriction or endothelium-dependent dila-
tion. Pulmonary arterial ring responses to treatment with KCl (A), PE (B),
time to peak contraction induced by PE (C), and ACh-induced dilation of
the KCl contraction (D) in WT and TRPC4-KO rats under control and
SU/Hx/Nx conditions. Data are expressed as means SEM. nZ 4 per group.
*P < 0.05 versus control; yP < 0.05 versus WT SU/Hx/Nx group.
TRPC4 and Mortality in Severe PAHeach of the ROIs was recorded over time (Figure 2C).
Individual endothelial cells from both WT and TRPC4-KO
rats exhibited one or two oscillations within the 2-minute
time period tested. Neither the total number of oscillatory
cells (sites) per minute nor the number of oscillatory events
per minute differed between groups (Figure 2C). In total, we
recorded 450 oscillatory events from 419 ROIs in WT rats
and 352 oscillatory events in 297 ROIs in KO rats; four
different animals were studied in WT and KO rats. Thus,
TRPC4 inactivation did not alter basal cytosolic calcium
oscillations in pulmonary artery endothelium.
ACh induces calcium store depletion from the endo-
plasmic reticulum and activates store-operated calcium entry
channels. Next, therefore, we examined whether TRPC4
inactivation impairs ACh-induced calcium inﬂux. ACh
application induced a transient, abrupt rise in cytosolic
calcium, which decayed to a plateau level over the 2-minute
time course of the experiment (Figure 2D). In TRPC4-KO
animals, the peak ACh-induced rise in cytosolic calcium
was normal, but the sustained increase in cytosolic calciumThe American Journal of Pathology - ajp.amjpathol.orgwas reduced, indicating that TRPC4 inactivation reduces the
sustained rise in cytosolic calcium. These results establish
that TRPC4-KO rats harbor a prominent calcium entry
defect.TRPC4 Inactivation Confers a Survival Beneﬁt in Severe
Pulmonary Arterial Hypertension
We next assessed the responses of WT and TRPC4-KO rats
to long-term (13 weeks) SU/Hx/Nx exposure. Based on
previous reports,30 SD rats tolerate severe pulmonary arte-
rial hypertension and right ventricular dysfunction for
extended durations. In stark contrast, none of the WT F344
rats survived the 13-week experimental period; however,
70% of the TRPC4-KO rats survived for 13 weeks, illus-
trating a clear survival beneﬁt after TRPC4 inactivation
(Figure 3).
With such unexpectedly high mortality in F344 rats, he-
modynamic parameters were obtained using echocardiog-
raphy in these animals only at baseline and at 8 weeks.
Normotensive KO rats tended to have smaller LVEDV,
compared with control WT rats (P Z 0.21) (Figure 3B).
Nonetheless, 8 weeks of SU/Hx/Nx exposure resulted in
similar decreases in CO (Figure 3C), TAPSE (Figure 3D),
and PA-AT in both WT and TRPC4-KO rats, relative to
control (Figure 3E).
In these studies, we noted that pulmonary hypertensive
F344 rats were highly sensitive to the 1.5% isoﬂurane used
to anesthetize animals for echocardiography measurements;
this sensitivity was especially evident in WT animals. A
precipitous decrease in CO (acute decompensation) in WT
animals was observed before death, an effect that was not1783
Figure 5 TRPC4 inactivation reduced the
magnitude of the arteriopathy after SU/Hx/Nx
exposure. A and B: Luminal occlusion density (OD)
of the small pulmonary arteries (<50 mm) was
graded in pulmonary hypertensive lungs of WT and
TRPC4-KO rats. The frequency of severely (>50%)
occluded vessels was higher in WT than in KO rats.
C: HeatheEdwards classiﬁcation of pulmonary
hypertension-induced vascular lesions. D: Examples
of severe ﬁbrinoid necrosis and perivascular
inﬂammation (grade VI, necrotizing arteritis) of
the pulmonary arteries in WT rats. Grading of le-
sions was performed in 50 arbitrarily chosen, but
consecutive, small pulmonary arteries per sample,
in three samples per experimental group. Signiﬁ-
cance was analyzed by likelihood ratio and Pear-
son’s P. ***P < 0.001. Scale bar Z 50 mm.
Alzoubi et alobserved in the KO rats. Therefore, although CO was
similar in WT and KO rats at baseline and after 5 weeks of
pulmonary hypertension (data not shown), WT rats had an
abrupt 40% reduction, compared with 7% reduction in KO
animals, in CO at the 8-week time point.
In an attempt to more deﬁnitively examine the hemody-
namic adaptations to SU/Hx/Nx, we repeated the exposure
and catheterized a subsequent set of rats after only 6 weeks
of pulmonary arterial hypertension. However, there was no
signiﬁcant difference in the average RVSP, CO, LVSP, or
right ventricular hypertrophy index between WT and
TRPC4-KO rats at 6 weeks (data not shown). Thus, echo-
cardiography and catheterization data taken together indi-
cate that the baseline hemodynamic adaptation to SU/Hx/Nx
is similar in WT and TRPC4-KO rats, but that WT rats are
more prone to acute cardiac decompensation and death.TRPC4 Channels Are Critical for Pulmonary and
Systemic Vasoreactivity
Calcium inﬂux via TRPC4 channels contributes to smooth
muscle contraction31 and leads to increased production of
nitric oxide in vascular endothelial cells.22 We therefore
determined the pulmonary arterial response to vasoactive
agents in WT and TRPC4-KO rats. Pulmonary artery1784vasoreactivity responses to KCl (Figure 4A) and PE
(Figure 4B) were similar in normotensive WT and TRPC4-
KO rats. KCl- and PE-induced constriction was slightly
augmented after development of pulmonary arterial hy-
pertension, but the difference did not reach statistical sig-
niﬁcance. Interestingly, although the recorded PE-induced
pulmonary vasoconstriction was almost equivalent in
SU/Hx/Nx-exposed WT and TRPC4-KO rats, the time to
peak contraction was lower in KO animals, suggesting that
the contractile mechanism is more efﬁcient after TRPC4
inactivation (Figure 4C). ACh caused an approximate 50%
relaxation to the KCl-induced constriction in normotensive
rats, irrespective of TRPC4 status (Figure 4D). This
endothelium-dependent relaxation was impaired in Su/Hx/
Nx-exposed animals, and ACh induced only a 20%
relaxation in vessels obtained from either WT or TRPC4-
KO rats.TRPC4 Inactivation Reduces Severity of the Occlusive
Pulmonary Arteriopathy and Cardiac Fibrosis in Severe
Pulmonary Arterial Hypertension
To further gauge the role TRPC4 channels play in severe
pulmonary arterial hypertension, we performed extensive
histopathological analyses of pulmonary vascular andajp.amjpathol.org - The American Journal of Pathology
Figure 6 Both WT and TRPC4-KO rats exhibited
cardiac ﬁbrosis after SU/Hx/Nx exposure. A: Mas-
son’s trichrome staining of the RV and LV in WT
and TRPC4-KO rats after 6 weeks of SU/Hx/Nx
exposure; collagen ﬁbers stain blue. Perivascular
ﬁbrosis (arrows) and interstitial ﬁbrosis (aster-
isks) tended to be higher in both ventricles of the
WT rats. Boxed regions correspond to the higher
magniﬁcation images to the right. B: Quantiﬁca-
tion of the ﬁbrotic zones in both ventricles
revealed no signiﬁcant difference between WT and
TRPC4-KO hearts. Data are expressed as means 
SEM. n Z 4 per group. Scale bar Z 50 mm.
TRPC4 and Mortality in Severe PAHcardiac remodeling. Small pulmonary arteries (<50 mm)
were ﬁrst graded based on luminal occlusion (Figure 5A).
The frequency of severely (>50%) occluded pulmonary
arteries was lower in TRPC4-KO rats than in WT rats
(Figure 5B; likelihood ratio and Pearson P value of
<0.001). In addition, there was an increase in the density of
fully patent pulmonary arteries (0% occlusion) in the KO
animals. To acquire a better survey of pulmonary vascular
remodeling in these rats, we categorized pulmonary arterial
lesions according to the HeatheEdwards classiﬁcation29
(Figure 5C). Such a thorough approach revealed two key
ﬁndings, that the number of mature plexiform lesions (grade
4) per lung was lower in KO rats and that some WT lungs
exhibited a severe form of ﬁbrinoid necrosis within the
pulmonary arteries (necrotizing arteritis), coupled with
perivascular inﬂammation (grade VI) (Figure 5D; likelihood
ratio and Pearson P value <0.001). Thus, TRPC4 inacti-
vation impairs development of the occlusive arteriopathy
prominent in severe pulmonary arterial hypertension.
We next evaluated the degree of cardiac ﬁbrosis, because
this is considered a terminal feature of maladaptive struc-
tural remodeling in the failing heart.32 The prevalence of
interstitial and perivascular collagen deposition within both
ventricles tended to be higher in WT than in KO rats,
although on average the difference did not reach statistical
signiﬁcance (Figure 6, A and B). Taken together with the
hemodynamic results, WT animals exhibited severe pul-
monary arterial hypertension characterized by maladaptive
remodeling of both the small precapillary arterioles and the
right and left ventricles, ultimately leading to heart failure
and death. Although TRPC4-KO rats developed severe
pulmonary arterial hypertension, occlusive vasculopathy
was less severe, and these animals were not as prone to
absolute heart failure.The American Journal of Pathology - ajp.amjpathol.orgDiscussion
We report here for the ﬁrst time the successful induction of
severe occlusive pulmonary arterial hypertension that pro-
gresses to heart failure and death in F344 rats. The observed
premature death of WT rats, and the reciprocal survival
beneﬁt in animals harboring a TRPC4 inactivation, are the
major highlights of the present study. The loss of TRPC4
channels in these rats corresponded to a milder form of
pulmonary vascular remodeling, seemingly disproportional
to their severe hemodynamic disturbances.
The importance of genetic mutations in the pathogenesis of
severe pulmonary arterial hypertension has been highlighted
in the most recent clinical classiﬁcation of the disease, in
which heritable forms were upgraded into a separate sub-
category.1 Germline mutations [eg, BMPR2, ACVRL1 (alias
ALK1), and endoglin (ENG)] have been evidenced in
approximately 70% of families with pulmonary arterial hy-
pertension,33 as well as in almost 20% of sporadic cases.34
To model for these mutations and to examine the mo-
lecular basis of disease, mice have been the main species
used, because of the ease and feasibility of genetic modiﬁ-
cation. However, critical anatomical, physiological, and
pathological differences between humans and mice have
hindered meaningful translational applications of the
research outcomes.35 Rats, in contrast, have shown promise
in replicating certain hallmarks of human pulmonary arterial
hypertension (eg, plexiform lesions), at least under certain
conditions.30,36 Unfortunately, the well-documented inter-
and intrastrain variability of rats, in addition to several other
technical challenges, has made these animals less favored
for genetics-oriented research.37 Our present study therefore
represents a signiﬁcant step forward. Here, we have pro-
vided evidence of a successful genetic modiﬁcation in F3441785
Alzoubi et alrats, namely, TRPC4 inactivation, which enables testing of
the role of TRPC4 in a severe form of pulmonary arterial
hypertension that is accompanied by reproducible induction
of angio-obliterative lesions with abject heart failure.
The use of SU/Hx/Nx exposure in SD rats is a landmark
event in the ﬁeld of pulmonary arterial hypertension
research, because the resulting hemodynamic and histo-
pathological changes in SD rats are highly conserved and
are comparable to those observed in patients.30,36 One major
departure from the natural history of the clinical disease,
however, is the surprising tolerance that these rats exhibit to
severely compromised cardiopulmonary status, and thus
their prolonged survival. We now report the ﬁrst evidence of
an animal model (ie, F344 rats exposed to SU/Hx/Nx) in
which the natural history of severe pulmonary hypertension
is accompanied by death, as occurs in the human disease.
Furthermore, we show for the ﬁrst time a mortality deter-
minant in SU/Hx/Nx-exposed rats, namely, expression of a
functional TRPC4 channel. The failure of currently avail-
able pulmonary arterial hypertension treatments to reduce
patient mortality38 points to the need for new drugs, and
TRPC4 could be an auspicious target.
The mechanism or mechanisms by which TRPC4 inac-
tivation reduces mortality in severe pulmonary arterial hy-
pertension requires further investigation. The past two
decades of research on pulmonary hypertension have yiel-
ded several insights into the pathogenic mechanisms of the
progressive and fatal disease. These include sustained pul-
monary vasoconstriction,39 occlusive vascular remodel-
ing,40 pulmonary and cardiac oxidative stress,41 metabolic
and endocrine disorders,42 and inﬂammation.43 At the sub-
cellular and molecular levels, disturbances in ion channels44
and mitochondrial function45 have also been implicated in
the pathogenesis of pulmonary hypertension, as have aber-
rations in signaling pathways, such as the Rho kinase
pathway.46 In light of these ﬁndings, we tested putative
mechanisms that could explain the observed survival beneﬁt
in TRPC4-KO rats. Because activation of store-operated
calcium entry is a stimulus for smooth muscle contraction,
we initially considered the possibility that TRPC4 inacti-
vation may decrease pulmonary arterial pressure and pro-
vide a survival beneﬁt. However, this effect on smooth
muscle tone might be counterbalanced by TRPC4-induced
release of endothelium-derived relaxing factors, particu-
larly nitric oxide, as reported by Freichel et al.22
In the present study, both WT and TRPC4-KO rats
developed the same degree of stable hemodynamic
compromise, in the forms of severely elevated RVSP,
diminished CI, and reduced TAPSE. Impairment of
endothelial-dependent relaxation was not observed in iso-
lated pulmonary arterial segments (ACh, 10 mmol/L).
Although the magnitudes of receptor-dependent (PE, 1
mmol/L) and receptor-independent (KCl, 80 mmol/L) con-
tractions were similar in WT and TRPC4-KO animals, the
time to peak contraction was improved in KO animals,
suggesting an increase in the efﬁciency of contraction. Our1786data therefore do not support the idea that TRPC4 inacti-
vation reduces (or worsens) the magnitude of pulmonary
arterial hypertension. Rather, the present ﬁndings suggest
that high pulmonary arterial pressures are not sufﬁcient to
cause heart failure and death in the absence of other exac-
erbating factors.
We next considered whether TRPC4 is an essential
determinant of vascular remodeling. This idea is supported
by reports linking TRPC4 channels to vascular endothelial
and smooth muscle cell proliferation.11,47 In support of this
idea, the severity of pulmonary arterial occlusions and the
number of plexiform lesions were substantially reduced in
KO rats, especially the complex lumen-occluding lesions.
Nonetheless, TRPC4 inactivation did not abolish lesion
formation; rather, it appeared to delay the onset and severity
of lesion formation. Although such a decrease in the
magnitude of occlusive remodeling undoubtedly reﬂects
improved vascular function, it is unlikely that this
improvement is sufﬁcient to account for the observed sur-
vival beneﬁt. Moreover, questions remain as to whether
occlusive remodeling is sufﬁcient to cause heart failure and
death. Drugs such as prostacyclin analogs can improve
functional status of pulmonary arterial hypertension pa-
tients, despite evidence from postmortem autopsies that they
increase the number of plexiform lesions.48 Furthermore,
SU/Hx/Nx-exposed SD rats develop severe plexogenic
arteriopathy with middle- and late-stage pulmonary arterial
hypertension, but they survive long after these lesions
become prominent.
We next considered whether TRPC4 inactivation im-
proves cardiac, renal, and hepatic adaptation to pulmonary
arterial hypertension. In animals with severe pulmonary
arterial hypertension that were hemodyamically stable, he-
modynamic and echocardiographic signs of cardiac failure
were similar in WT and TRPC4-KO rats. However, acute
declines in CO predicted early mortality in WT rats, an
effect that was not apparent in KO rats. Moreover, the de-
gree of structurally maladaptive remodeling (ie, ﬁbrosis)
was more pronounced in WT rats. In fact, the biventricular
nature of this ﬁbrosis in WT rats was surprising, given our
previous observation that left ventricles of SD rats with
severe pulmonary arterial hypertension were consistently
spared from signiﬁcant structural changes.49 Although WT
rats exhibited evidence of cardiac failure, ﬁndings from
kidney and liver function tests were inconclusive, because
laboratory values mostly fell within normal ranges for both
groups of rats (data not shown).
Overall, the present study offers novel insights into the
role of TRPC4 channels in severe pulmonary arterial hy-
pertension and uniquely validates the prospect of using
genetically modiﬁed rats as a preclinical model of disease.
Based on the present results, we conclude that TRPC4
inactivation reduces mortality associated with severe pul-
monary arterial hypertension, at least in part by decreasing
both the magnitude of occlusive remodeling and the sus-
ceptibility to heart failure.ajp.amjpathol.org - The American Journal of Pathology
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